P2X7受体在非小细胞肺癌中的表达及其临床意义*

The expression of P2X7 receptor in non-small cell lung cancer and its clinical significance*

摘要:

的?探讨非小细胞肺癌（NSCLC）患者癌组织中P2X7R的表达及其临床意义。方法?回顾性分析2012年1月—2014年1月华中科技大学同济医学院附属武汉中心医院收治的NSCLC患者118例癌组织标本。采用免疫组织化学法检测NSCLC组织标本中P2X7R的表达，根据免疫组织化学结果将患者分为P2X7R高、低表达组。采用Kaplan-Meier曲线和Log-rank χ2检验比较P2X7R高、低表达组无瘤生存率和总生存率的差异；采用Cox比例风险模型分析影响NSCLC患者无瘤生存率和总生存率的独立危险因素。 结果?72例（61.0%）患者癌组织中P2X7R高表达。不同TNM分期和有无淋巴结转移患者的P2X7R蛋白高表达率比较，差异有统计学意义（P?<0.05）。P2X7R高表达组5年无瘤生存率低于P2X7R低表达组（18.1% VS 25.1%）（P?<0.05）；P2X7R高表达组5年总生存率低于P2X7R低表达组（23.3% VS 30.1%）（P?<0.05）。单因素Cox比例风险模型分析显示，P2X7R表达、TNM分期及淋巴结转移是影响NSCLC患者无瘤生存率的危险因素（P?<0.05）。多因素Cox比例风险模型分析表明，P2X7R表达[OlR=2.082（95% CI：1.079，3.747），P?=0.001]及TNM分期[OlR=3.210（95% CI：0.587，6.448），P?=0.028]是影响NSCLC患者无瘤生存率的危险因素。单因素Cox比例风险模型回归分析显示，P2X7R表达、TNM分期和淋巴结转移是影响NSCLC患者总生存率的危险因素（P?<0.05）。多因素Cox比例风险模型回归分析表明，P2X7R表达[OlR=2.893（95%CI：1.582，4.562），P?=0.002]及TNM分期[OlR=1.910（95%CI：0.587，2.449），P?=0.038]是影响NSCLC患者总生存率的危险因素。结论?P2X7R表达可作为影响NSCLC预后的新分子标志物。

Abstract:

Objective To investigate the expression of P2X7 receptor (P2X7R) in cancer tissues of patients with non-small cell lung cancer (NSCLC) and its clinical significance. Methods The clinical data of 118 patients with NSCLC admitted to our hospital from January 2012 to January 2014 were retrospectively analyzed. The expression of P2X7R in NSCLC tissue samples was detected by immunohistochemistry. According to the results of immunohistochemistry, the patients were divided into the high expression of P2X7R group and the low expression of P2X7R group. Kaplan-Meier curve method and log-rank test were used to compare the tumor-free survival rate and overall survival rate of the high and low expression P2X7R group. Cox proportional hazard model was used to analyze the independent risk factors affecting the tumor-free survival rate and overall survival rate of NSCLC patients. Results In cancer tissues of 72 (61.0%) patients with NSCLC, P2X7R was highly expressed. There was a significant difference in the expression of P2X7R among different TNM stages (P?